AzTrials
AzTrials

TraumaPhase 4NCT04166877

Magnesium Infusion for Pain Management in Critically Ill Trauma Patients

A Phase 4 study testing Magnesium Sulfate in Parenteral Dosage Form in people with Trauma and Acute Pain, run by University of California, Davis at 1 site in United States.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

Magnesium is a naturally occurring mineral that is important for your body and brain. Magnesium sulfate (study drug) is a medication containing magnesium that is commonly used to improve low blood levels of magnesium. Magnesium sulfate has also proven to be successful in managing pain before and after surgery. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Trauma, Acute Pain
What is being tested?
Magnesium Sulfate in Parenteral Dosage Form
Type of treatment
Injection or infusion
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
156 participants
Where
1 siteUnited States
Study dates
7 Dec 2019to 31 Dec 2026
Phase
Phase 4
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • All trauma patients admitted to an adult intensive care unit
  • Signed informed consent
  • Hospital or trauma multimodal pain management order set used for pain management
  • Ages 18-99

Who cannot join

  • Admission to the Pediatric Intensive Care Unit.
  • Head Abbreviated Injury Score (AIS) of greater than 1
  • Known heart failure with reduced ejection fraction (EF < 40%)
  • Renal failure (GFR < 60)
  • Cardiac arrhythmia (except for sinus tachycardia)
  • Greater than 5% TBSA burn injuries
Show all 14Show fewer
  • Moderate to severe alcohol withdrawal protocol ordered for patient
  • Regular use of opioids in the week prior to injury
  • Receiving continuous infusion of opioids
  • Patients expected to require general anesthesia between 24 and 48 hours after admission (during study drug administration)
  • Patients unable to provide consent is unavailable
  • Patients unable to provide a pain score
  • Pregnancy
  • Prisoners

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Christine S Cocanour, MD contact

9167347330

cscocanour@ucdavis.edu

G J Jurkovich, MD contact

9167348298

gjjurkovich@ucdavis.edu

United States1 site, 1 recruiting
  • UC Davis Health

    Sacramento, California, 95817

    Christine S Cocanour, MD

    Recruiting

Other trials in United States

About this study

Magnesium is a naturally occurring mineral that is important for your body and brain. Magnesium sulfate (study drug) is a medication containing magnesium that is commonly used to improve low blood levels of magnesium. Magnesium sulfate has also proven to be successful in managing pain before and after surgery. However, this drug has primarily been used for pain control in patients undergoing surgery. Patients in the ICU with injuries also need good pain control. Using magnesium may assist in decreasing narcotic (pain reliever) requirements and provide another non-narcotic drug for pain control.

The purpose of this study is to test the effectiveness of continuous, intravenous (into or within a vein using a needle) administration of magnesium sulfate for pain control in trauma patients admitted to the adult Intensive Care Unit. This will be compared to intravenous normal saline (salt solution).

Read the detailed description

This is a single center, double blind, randomized controlled study to demonstrate the effectiveness of continuous, intravenous administration of magnesium sulfate as compared to placebo in decreasing pain in critically injured patients.

Study Hypothesis The primary hypothesis is that continuous infusion magnesium sulfate will significantly decrease opioid requirements and pain scores in critically ill patients.

Background Magnesium is one of the most abundant cations in the human body. The physiologically active form of magnesium, ionized magnesium, is involved in hundreds of enzyme reactions that are important for homeostasis, action potentials, and membrane stability, among others.[Seo, et al] Hypomagnesemia is one of the most common electrolyte disturbances in the hospitalized patient, especially in the critically ill population. Studies have established that low magnesium levels increase mortality and morbidity in the critically ill patient,[Upala, et al] and thus magnesium is often repleted with intermittent infusion. Outside of its role in enzyme reactions, magnesium was discovered to have analgesic effects approximately twenty years ago.[Albrecht, et al] It appears to potentiate morphine analgesia, attenuate morphine tolerance, and suppress neuropathic pain.[Albrecht, et al] At a mechanistic level, these effects are thought to be secondary to magnesium regulating calcium influx into cells and antagonizing NMDA receptors in the central nervous system.

Magnesium has long been utilized in prevention and management of preeclampsia and eclampsia. A typical dosing regimen in this setting involves a 4 g loading dose of magnesium sulfate, followed by a magnesium infusion of 1-2 g/hr. When compared to eclampsia regimens, studies investigating the role of magnesium sulfate in multimodal surgical pain management consistently use lower doses. Even with this dosing, multiple trials have shown reduced postoperative pain and analgesic requirements.[Albrecht, et al, Sousa, et al, Hwang, et al, Shariat, et al] In one example, Shariat Moharari and others used a regimen of 40 mg/kg magnesium bolus followed by 10 mg/kg/hr infusion in perioperative gastrointestinal surgery patients, without adverse effects.[Shariat, et al]

Normal reference range for serum magnesium has been defined as approximately 0.7-1 mmol/L (1.5-2 mEq/L or 1.7-2.4 mg/dL).[Williamson, et al] Tramer et al. reported that a 3 g bolus dose of magnesium sulfate followed with 0.5 g/hr infusion for 20 hours resulted in an increase from baseline serum magnesium of approximately 0.6 mmol/L. Despite the higher post-treatment serum magnesium levels in the treatment group, no difference in safety outcomes was noted in comparison to the control group receiving 0.9% sodium chloride.[Tramer,et al] Similarly, Ozcan et al. found that 30 mg/kg bolus dose of magnesium sulfate followed by infusion of 10 mg/Kg/hr for 48 hours resulted in an increased serum magnesium level from baseline by approximately 0.7 mmol/L. The noted increase in serum magnesium level in this study also did not translate into any difference in safety endpoints between the intervention group and control group receiving 0.9% sodium chloride.[Ozcan, et al] Initial signs of magnesium toxicity following administration of magnesium sulfate have been reported to occur at serum magnesium levels greater than 3.5-5 mmol/L.[Lu, et al, Jahnen-Dechent, et al]

Despite the successful use of magnesium in perioperative pain management, it has yet to be applied in patient populations outside of the operating room. Given the need for adequate pain control among critically ill patients with traumatic injuries, the use of magnesium for pain management may assist in decreasing opioid requirements and provide another non-opioid adjunct for pain control.

Methods:

All trauma patients admitted to an adult ICU are screened during the first 24 hours after admission. If they meet criteria for admission to the study, an informed consent will be obtained. Patients meeting eligibility will be randomized by the Investigational Drug Service in a computer-generated, blinded block, 1:1 ratio to treatment with either magnesium sulfate (diluted appropriately in normal saline per standard procedures) or placebo (normal saline)."

Opioid administration will be recorded per usual nursing protocol in the electronic medial record. Heart rate, mean arterial pressure (MAP), respiratory rate, and RASS will be recorded at least every two hours per unit protocol.

A study worksheet will be posted at bedside for consistent collection of pain scores and CAM. Pain will be assessed per unit protocol using the numeric rating scale, with zero representing no pain and ten representing the worst pain imaginable.

The EMR will be reviewed; opioid administration, pain scores, and vital signs will be transferred to a separate data sheet through REDCap (Research Electronic Data Capture) software.

The primary outcome measure will be the total opioid requirement during the 24 hours of magnesium infusion. We performed this power analysis based on a recent retrospective cohort study performed at our institution.[Hamrick, et al] We estimate that the 24 hour OME requirement will decrease from 70 mg in the control group to 50 mg in the treatment group, with a standard deviation of 50 mg in each group, leading to an effect size of 0.4. Using the statistical program G*Power 3.0.1 with an effect size of 0.4, alpha of 0.05, power of 0.8, and equal allocation ratios, a sample size of 78 patients per group would be required.

Data will be assessed for normality by assessing distribution skewness and kurtosis. Depending on these results, t-tests or Wilcoxon rank-sum tests for two groups will be used to assess the primary outcome of total opioid dose. Other data, including pain scores, that is collected repeatedly will be analyzed with two-way repeated measures analysis of variance, with subsequent pair-wise comparison for any significant findings. Statistical significance will be set at a P value of less than 0.05. We will use SAS to perform the statistical analysis.

Conditions
Trauma, Acute Pain
Being tested
Magnesium Sulfate in Parenteral Dosage Form, Normal saline placebo
Keywords
magnesium sulfate, trauma, acute pain
Medical subject headings
Wounds and Injuries, Acute Pain

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Magnesium Sulfate in Parenteral Dosage FormDrug

    IV bolus followed by continuous infusion for 24 hours

  • Normal saline placeboDrug

    IV bolus followed by continuous infusion for 24 hours

Study groups in NCT04166877
Study groupRoleWhat they receive
Magnesium GroupExperimentalThe magnesium group arm will receive a 40 mg/kg IBW (maximum 4 g) bolus of intravenous magnesium sulfate, followed by a continuous infusion of 0.5 g/hr for a total of 24 hours.
Receives: Drug: Magnesium Sulfate in Parenteral Dosage Form
Control GroupPlacebo comparatorThe control arm will receive the same volume and rate of saline as if they were in the experimental group.
Receives: Drug: Normal saline placebo

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. total opioid requirements during study drug infusion

    oral morphine equivalents, OME

    Measured: 24 hours during study drug infusion

Secondary outcomes (9)
  1. pain scores

    numeric pain rating scale as reported by patient

    Measured: daily x 4 days

  2. Total oral morphine equivalents

    Measured: daily x 4 days

  3. ICU length of stay

    Measured: through the patient's hospitalization for this injury, an average of 10 days

  4. ICU-free days

    14 days minus the number of ICU days

    Measured: 14 days

  5. Hospital length of stay

    Measured: through the patient's hospitalization for this injury, an average of 10 days

  6. Development of bradycardia

    Measured: 24 hours during study drug infusion

  7. Development of other dysrhythmia

    Measured: 24 hours during study drug infusion

  8. Respiratory depression

    Episodes of respiratory depression as measured by a respiratory rate less than 8

    Measured: 24 hours during study drug infusion

  9. Prevalence of Richmond Agitation-Sedation Scale of -3 to -5

    Episodes of a -3 to -5 Richmond Agitation-Sedation Scale score

    Measured: 24 hours during study drug infusion

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted18 Nov 2019
  2. Study start7 Dec 2019
  3. Primary completion31 Dec 2026 (estimated)
  4. Study completion31 Dec 2026 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Model description
Single center, investigator-initiated, randomized, double-blinded, placebo controlled study
Masking
Quadruple blind
Who is masked
Participant, Care provider, Investigator, Outcomes assessor
Enrolment
156 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04166877
Sponsor's protocol ID
1440730
Status last verified
Nov 2025
First submitted
13 Nov 2019
Last updated
26 Nov 2025
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
Individual data sharing
No

Publications

  • Seo JW, Park TJ. Magnesium metabolism. Electrolyte Blood Press. 2008 Dec;6(2):86-95. doi: 10.5049/EBP.2008.6.2.86. Epub 2008 Dec 31.

    PubMed 24459527
  • Upala S, Jaruvongvanich V, Wijarnpreecha K, Sanguankeo A. Hypomagnesemia and mortality in patients admitted to intensive care unit: a systematic review and meta-analysis. QJM. 2016 Jul;109(7):453-459. doi: 10.1093/qjmed/hcw048. Epub 2016 Mar 24.

    PubMed 27016536
  • Albrecht E, Kirkham KR, Liu SS, Brull R. Peri-operative intravenous administration of magnesium sulphate and postoperative pain: a meta-analysis. Anaesthesia. 2013 Jan;68(1):79-90. doi: 10.1111/j.1365-2044.2012.07335.x. Epub 2012 Nov 1.

    PubMed 23121612
  • Sousa AM, Rosado GM, Neto Jde S, Guimaraes GM, Ashmawi HA. Magnesium sulfate improves postoperative analgesia in laparoscopic gynecologic surgeries: a double-blind randomized controlled trial. J Clin Anesth. 2016 Nov;34:379-84. doi: 10.1016/j.jclinane.2016.05.006. Epub 2016 Jun 5.

    PubMed 27687417
  • Hwang JY, Na HS, Jeon YT, Ro YJ, Kim CS, Do SH. I.V. infusion of magnesium sulphate during spinal anaesthesia improves postoperative analgesia. Br J Anaesth. 2010 Jan;104(1):89-93. doi: 10.1093/bja/aep334.

    PubMed 19933175
  • Shariat Moharari R, Motalebi M, Najafi A, Zamani MM, Imani F, Etezadi F, Pourfakhr P, Khajavi MR. Magnesium Can Decrease Postoperative Physiological Ileus and Postoperative Pain in Major non Laparoscopic Gastrointestinal Surgeries: A Randomized Controlled Trial. Anesth Pain Med. 2013 Dec 6;4(1):e12750. doi: 10.5812/aapm.12750. eCollection 2014 Feb.

    PubMed 24660146
  • Hamrick KL, Beyer CA, Lee JA, Cocanour CS, Duby JJ. Multimodal Analgesia and Opioid Use in Critically Ill Trauma Patients. J Am Coll Surg. 2019 May;228(5):769-775.e1. doi: 10.1016/j.jamcollsurg.2019.01.020. Epub 2019 Feb 21.

    PubMed 30797081
  • Williamson M. A., Snyder L. M., Wallach J. B. Wallach's Interpretation of Diagnostic Tests. 9th. Philadelphia, PA, USA: Wolters Kluwer/Lippincott Williams & Wilkins; 2011. xvi, 1143.

  • Tramer MR, Schneider J, Marti RA, Rifat K. Role of magnesium sulfate in postoperative analgesia. Anesthesiology. 1996 Feb;84(2):340-7. doi: 10.1097/00000542-199602000-00011.

    PubMed 8602664
  • Ozcan PE, Tugrul S, Senturk NM, Uludag E, Cakar N, Telci L, Esen F. Role of magnesium sulfate in postoperative pain management for patients undergoing thoracotomy. J Cardiothorac Vasc Anesth. 2007 Dec;21(6):827-31. doi: 10.1053/j.jvca.2006.11.013. Epub 2007 Feb 7.

    PubMed 18068060
  • Lu JF, Nightingale CH. Magnesium sulfate in eclampsia and pre-eclampsia: pharmacokinetic principles. Clin Pharmacokinet. 2000 Apr;38(4):305-14. doi: 10.2165/00003088-200038040-00002.

    PubMed 10803454
  • Jahnen-Dechent W, Ketteler M. Magnesium basics. Clin Kidney J. 2012 Feb;5(Suppl 1):i3-i14. doi: 10.1093/ndtplus/sfr163.

    PubMed 26069819

Questions about this trial

What is this clinical trial studying?

A Phase 4 study testing Magnesium Sulfate in Parenteral Dosage Form in people with Trauma and Acute Pain, run by University of California, Davis at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 14 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 26 Nov 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Christine S Cocanour, MD (9167347330, cscocanour@ucdavis.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

total opioid requirements during study drug infusion (time frame: 24 hours during study drug infusion). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT04166877, which also lists 12 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 26 Nov 2025.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in